iSpecimen (iSpecimen) Debt-to-Equity

: 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

iSpecimen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.17 Mil. iSpecimen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. iSpecimen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $9.74 Mil. iSpecimen's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for iSpecimen's Debt-to-Equity or its related term are showing as below:

ISPC' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.47 Med: -0.18 Max: 0.12
Current: 0.02

During the past 6 years, the highest Debt-to-Equity Ratio of iSpecimen was 0.12. The lowest was -0.47. And the median was -0.18.

ISPC's Debt-to-Equity is ranked better than
94.92% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs ISPC: 0.02

iSpecimen Debt-to-Equity Historical Data

The historical data trend for iSpecimen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.47

0.12

0.01

0.02

iSpecimen Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity															0.01	0.01	0.01	0.02	0.02

Competitive Comparison

For the Diagnostics & Research subindustry, iSpecimen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iSpecimen Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where iSpecimen's Debt-to-Equity falls into.

iSpecimen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

iSpecimen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.167	+	0.029)	/	9.741
	=	0.02

iSpecimen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.167	+	0.029)	/	9.741
	=	0.02

iSpecimen (NAS:ISPC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

iSpecimen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of iSpecimen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

iSpecimen (iSpecimen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 Bedford Street, Lexington, MA, USA, 02420

Website

https://www.ispecimen.com

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Executives

Benjamin Bielak	officer: Chief Information Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley	officer: Chief Financial Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile	director	450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross	director, 10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d.	director	C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc	10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence	director	450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl	director	450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli	director, officer: CEO, President	450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan	director, officer: COO, Secretary, Treasurer	450 BEDFORD STREET, LEXINGTON MA 02420